Series Pre-A Financing completed with MP Healthcare Venture Management Inc. and Eisai Innovation Inc.

SOL-257, an experimental gene therapy developed by SOLA Biosciences, has shown encouraging preclinical results by slowing disease progression and significantly extending survival in a mouse model of amyotrophic lateral sclerosis (ALS) through targeting toxic, misfolded TDP-43 protein that drives neuronal damage. The therapy, presented at a major neuromuscular disease research

Positive data of animal efficacy study data of SOL-257 on the ALS/TDP43 mouse model was presented by Dr. Akinori Hishiya, CSO of SOLA Biosciences.